Schizophrenia Clinical Trial
Official title:
Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study
Verified date | November 2017 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this pilot study is to evaluate the impact of switching 30 subjects from an existing antipsychotic to risperidone long acting on healthcare resource utilization. The study will be a ten month open-label, 'mirror-image', pilot study. Healthcare resource utilization during the 10 months prior to starting risperidone long acting will be retrospectively collected for all subjects (period A) at the beginning of the study. The utilization of direct medical resources will also be collected for 10 months after initiation of risperidone long acting (period B). In this design the patients will serve as their own control.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Subjects with a diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV criteria. - Men and women, aged 18-65 years. - Subjects must be able to give written informed consent. - Subjects must be inpatients. - Subjects must have adequate data to assess healthcare resource utilization for the previous 10 months. - Subjects must have been previously treated with (and tolerated) oral risperidone. - Results of standard clinical laboratory tests are to be within the laboratory's reference range or, if outside this range, judged by the investigator to be not clinically significant. Exclusion Criteria: Exclusion Criteria: - Subjects with significant alcohol or substance abuse in the past 3 months. - Subjects with other psychiatric, medical or behavioural comorbid disorder that in the opinion of the investigator may interfere with study conduct or interpretation (such as delirium, stroke, developmental disability). - Subjects who are pregnant, breast-feeding, or women of child-bearing potential not using adequate contraception. - Subjects with known hypersensitivity or allergy to risperidone. - Subjects with tardive dyskinesia or a history of neuroleptic malignant syndrome. - Subjects with a known history of being unresponsive to risperidone. - Subjects with a clinically significant electrocardiogram abnormality. |
Country | Name | City | State |
---|---|---|---|
Canada | Riverview Hospital | Coquitlam | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Riverview Hospital |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the impact of switching subjects from an existing antipsychotic to risperidone long acting on healthcare resource utilization. This will be evaluated by assessing: | |||
Primary | Direct cost of care | |||
Primary | Frequency and duration of institutional care | |||
Primary | Discharge | |||
Primary | Relapse | |||
Secondary | To determine if effectiveness is maintained for subjects switched from an existing antipsychotic to risperidone long acting. This will be evaluated by assessing: | |||
Secondary | Positive and negative symptoms (PANSS) | |||
Secondary | Overall illness severity (CGI severity, CGI improvement) | |||
Secondary | Social and occupational functioning (SOFAS), and | |||
Secondary | Remission | |||
Secondary | To evaluate the safety and tolerability of risperidone long acting. This will be evaluated by assessing: | |||
Secondary | Extrapyramidal symptoms (ESRS) | |||
Secondary | Side effects (UKU side effect rating scale) | |||
Secondary | Akathisia (Barnes akathisia scale) | |||
Secondary | Quality of life (SF-36) | |||
Secondary | Weight, and waist circumference | |||
Secondary | Hematology (fasting glucose and lipid analysis) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |